Literature DB >> 18537759

Statins as antihypertensives.

Carlos A Feldstein1.   

Abstract

The beneficial effects of statins in hypertension stem from their effects on endothelial function, their interactions with the renin-angiotensin system, and their influence on large artery compliance. Substantial evidence has recently accumulated showing that statins exert pleiotropic effects in vascular function. These include an increase in the synthesis of NO, inhibition of vascular smooth muscle cell proliferation and migration, anti-inflammatory actions, downregulation of angiotensin II type 1 receptor expression, and anti-oxidative effects. These effects occur before reduction of cholesterolemia. Available data support only a modest BP-lowering effect of statins which is most prominent in those patients with poorly controlled hypertension. Even though they only cause a minor reduction in BP, they may play a role in the prevention of cardiovascular disease. Statins may be useful therapeutic agents in hypertensives with high serum total cholesterol, in patients with poorly controlled hypertension even without hypercholesterolemia, in normocholesterolemic well-controlled hypertensive subjects with high C reactive protein levels, and in those subjects who need secondary prevention. Future research is needed to further characterize the impact of statins alone or in combination with antihypertensive agents to prevent or delay the development of stage 1 hypertension. This review article also includes relevant patents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537759     DOI: 10.2174/157489008784705331

Source DB:  PubMed          Journal:  Recent Pat Cardiovasc Drug Discov


  4 in total

1.  Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.

Authors:  Richard Grimm; Mobin Malik; Carla Yunis; Santosh Sutradhar; Attila Kursun
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

2.  PrEP Implementation Science: State-of-the-Art and Research Agenda.

Authors:  Carlos F Cáceres; Kenneth H Mayer; Rachel Baggaley; Kevin R O'Reilly
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

3.  The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.

Authors:  Carlos F Cáceres; Florence Koechlin; Pedro Goicochea; Papa-Salif Sow; Kevin R O'Reilly; Kenneth H Mayer; Peter Godfrey-Faussett
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

4.  Current Perspectives on rosuvastatin.

Authors:  Miao Hu; Brian Tomlinson
Journal:  Integr Blood Press Control       Date:  2013-04-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.